Department of Infectious Diseases, St.
George's Hospital Medical School, London SW17 ORE, United Kingdom
Heterosexual transmission of human immunodeficiency virus (HIV) is
the most frequent mode of infection worldwide. However, the immediate
events between exposure to infectious virus and establishment of
infection are still poorly understood. This study investigates
parameters of HIV infection of human female genital tissue in vitro
using an explant culture model. In particular, we investigated the role
of the epithelium and virucidal agents in protection against HIV
infection. We have demonstrated that the major target cells of
infection reside below the genital epithelium, and thus HIV must cross
this barrier to establish infection. Immune activation enhanced HIV
infection of such subepithelial cells. Furthermore, our data suggest
that genital epithelial cells were not susceptible to HIV infection,
appear to play no part in the transfer of infectious virus across
the epithelium, and thus may provide a barrier to infection.
In addition, experiments using a panel of virucidal agents demonstrated
differential efficiency to block HIV infection of subepithelial cells
from partial to complete inhibition. This is the first demonstration
that virucidal agents designed for topical vaginal use block HIV
infection of genital tissue. Such agents have major implications for
world health, as they will provide women with a mechanism of personal and covert protection from HIV infection.
 |
INTRODUCTION |
Heterosexual transmission of human
immunodeficiency virus (HIV) infection occurs through mucosal surfaces
and is the major route of infection worldwide. This mode of
transmission is increasing in prevalence more rapidly than any other in
the West (31, 33, 42). Male-female transmission rates (per
contact infectivity estimated to be 0.0009 in North American women) are
reported to be approximately eight times more efficient than
female-male rates, with history of concomitant sexually transmitted
diseases (STDs) being the most strongly associated risk factor
(22). Conflicting data have been reported on the selective
pressure of mucosal transmission on the phenotypic and genotypic
characteristics of transmitted viral isolates from a heterogeneous
inoculum. Predominant isolation from peripheral blood of virus able to
infect both macrophages and CD4+ T lymphocytes
(non-syncytium inducing [NSI], M-tropic) over those that
preferentially infect T lymphocytes (syncytium inducing [SI], T-tropic), during or near to acute HIV infection have lead to the
suggestion that NSI viruses may be more readily transmitted via mucosal
routes (40). The mechanisms for such selective transmission of HIV isolates may be one of either selective penetration or selective
amplification within the infected host (33). Analyses of
genital biopsies from HIV-infected women and preliminary studies from
this laboratory, using cervical organ culture as a model of primary
infection, have demonstrated that HIV-infected cells reside within
subepithelial mucosa, with no evidence of HIV infection of epithelial
cells (20, 21, 23, 27, 35). Furthermore, it has been
demonstrated that the primary targets of simian immunodeficiency virus
(SIV) infection, following intravaginal infection of macaques, are
cervical and vaginal subepithelial cells (35). Such data indicate that establishment of HIV infection requires transepithelial penetration. Whether intact genital epithelium presents a barrier to,
or is an active participant in, HIV transmission has not been tested in
primary human mucosal tissue.
Epithelium along the female genital tract differs in structural
cellular organization: the vagina and ectocervix, the site most exposed
to a natural inoculum, are composed of stratified epithelium, whereas
the endocervix is composed of a single epithelial monolayer. Multiple
mechanisms for HIV transmission across genital epithelia have been
proposed: direct HIV infection of epithelial cells, transcytosis of HIV
through epithelial cells, epithelial transmigration of HIV-infected
donor cells, uptake of HIV by intraepithelial Langerhans cells, or
circumvention of epithelium via breaches in epithelial integrity
(14, 33). Evidence for HIV infection of, or transcytosis
through, epithelial cells is derived from in vitro studies using
epithelial cell lines, which may bear little relation to primary intact
genital epithelium (1, 38). Furthermore, infection or
transcytosis in such models is dependent on cell-associated virus, an
observation at odds with efficient mucosal cell-free SIV or feline
immunodeficiency virus infection (3, 35). Strong epidemiological association of inflammatory ulcerative venereal disease
with HIV transmission and observation that mucosal SIV transmission may
be enhanced following thinning of vaginal epithelium by progesterone
implants suggests a barrier role for genital epithelium (18,
31). Furthermore, recent studies have demonstrated that STDs
increase both the number of CD4 cells in genital mucosa and the
expression of chemokine receptors known to function as HIV coreceptors,
thereby increasing the number of target cells (16, 24, 30).
While HIV may achieve transepithelial penetration by more than one
mechanism, the relatively low incidence of per-contact infectivity
suggests that this is unlikely to reflect a constitutive mechanism.
However, male-female transmission is also influenced by factors
relating to the male partner, including seminal viral load and
incidence of STDs (31), all of which have an impact on
contact infectivity.
While condoms provide an effective barrier against transmission of HIV
and other STDs, they require the consent of the male partner, which
cannot always be negotiated by women at risk for infection. Thus, there
is an urgent need to develop prevention strategies that are under the
personal control of women. The potential of effective topical vaginal
virucides to prevent sexual transmission of HIV and other STDs is
widely recognized (8). However, proper evaluation of the
efficacy of such agents in blocking HIV infection of female genital
tissue has been hampered by the lack of appropriate experimental models.
Thus, understanding the first critical events in genital mucosal
transmission of HIV infection is important in developing strategies to
block or limit such transmission. In this study, human genital mucosal
tissue from premenopausal seronegative women was been used to define
primary target cells for HIV infection within genital mucosa,
differential susceptibility of such tissue to M-tropic and T-tropic HIV
isolates, and the interaction of HIV with genital epithelium.
Furthermore, this in vitro model has been used to determine the
efficacy of potential vaginal virucides designed to protect women from
HIV infection.
 |
MATERIALS AND METHODS |
Virus culture and infection.
The following strains of HIV-1
were used in this study: BaL (grown in monocyte-derived macrophages),
RF and IIIB (grown in H9 cells) (AIDS reagent project, National
Institute for Biological Standards and Control, Potters Bar, United
Kingdom), and SL-2, 2044, and 2076 (generously donated by Paul Clapham,
Imperial Cancer Research Fund, United Kingdom) grown in
phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cell
(PBMC) cultures. Cell-free viral preparations were passed through
0.2-µm-pore-size filters and treated with DNase I (Sigma Ltd., Poole,
United Kingdom) prior to use (100 U/ml, 5 mM MgCl2, 30 min
at 37°C). Chronically infected PM-1 T cells (AIDS reagent project)
were produced by continual culture (RPMI 10% [RPMI 1640 medium
supplemented with 10% fetal calf serum, penicillin, streptomycin, and
L-glutamine]) of these cells following exposure to the BaL
or RF strain of HIV-1. Chronically infected PBMC cultures were
established following infection of PHA-stimulated PBMC cultures with
HIVBaL. Infection was monitored by p24 antigen release,
measured by enzyme-linked immunosorbent assay (ELISA; DuPont NEN,
Hounslow, United Kingdom) according to the manufacturers protocol.
Chronically infected cells were treated with mitomycin C (200 µg/ml;
Sigma) for 1 h at 37°C prior to use (38).
Culture of human genital tract tissue explants and HIV
infection.
Cervical and vaginal tissue were obtained from
premenopausal women undergoing planned therapeutic hysterectomy at St.
George's and St. Helier Hospitals, London, United Kingdom. Cervical
and vaginal explants, comprising of both epithelial and stromal tissue, were produced using either 3- or 8-mm-diameter biopsy punches as
described below. Intact explants (3 mm) were cultured on squares of
stainless-steel mesh, individually, in 24-well flat-bottomed plates so
that a meniscus of culture medium (Eagle's minimal essential medium
supplemented with penicillin, streptomycin, L-glutamine, and HEPES buffer [EMEM], Sigma) was in contact with the under surface
of the grid, as previously described (23). In some
experiments, where indicated, explants were directly cultured in 300 µl of RPMI 10% in a 96-well plate. Explants were incubated at 37°C
in a humidified atmosphere containing 5% CO2, and
two-thirds of the medium was changed every 2 to 3 days, taking care not
to disturb any migratory cells within the culture wells. Two protocols
were used for HIV infection of explant tissue. Initially, explants were
cultured for 2 days prior to infection in either the absence or
presence of PHA (5 µg/ml). Explants were then exposed to viral isolates by immersion in 1 ml of cell-free virus (103 to
106 50% tissue culture infective doses
[TCID50]) for 2 h at 37°C. After incubation with
infectious virus, explants were washed a minimum of five times in
phosphate-buffered saline (PBS) and then cultured on grids as described
above. Explants stimulated with PHA were cultured in the presence of
interleukin-2 (IL-2; 10 U/ml; AIDS reagent project) throughout the
experiment. After 8 days, explants were processed for
immunohistochemistry or PCR. Remaining tissue was transferred to
96-well plates, cultured in medium (RPMI 10%) alone or restimulated by
culture in the presence of PHA (5 µg/ml) for 2 days, and subsequently
refed with medium containing IL-2. Culture medium was collected every 2 to 3 days and stored at
70°C before subsequent measurement of p24
antigen content by ELISA. For later experiments, explants were exposed
to viral innoculum, by immersion in cell-free virus (103 to
106 TCID50) for 2 h at 37°C, within
4 h of isolation. Subsequently explant tissue was washed in PBS as
described above, and tissue was directly transferred to 96-well plates,
cultured in medium (RPMI 10%) alone or stimulated by culture in the
presence of PHA (5 µg/ml) for 2 days, and subsequently refed with
medium containing IL-2. In both culture models, any migratory cells
were retained within the culture wells through out the experiment.
Preparation of epithelial sheets and primary epithelial
cultures.
Cervical epithelial sheets were isolated from 8-mm
biopsies following enzymatic digestion using dispase II (Boehringer
Mannheim Ltd., Lewes, United Kingdom) and trypsin-EDTA (Sigma). Tissue was incubated in dispase overnight at 4°C. The following day, biopsies were washed three times in PBS to remove dispase and the
epithelial cells were separated from the submucosa using fine forceps
as previously described (15). Ectocervical epithelium (released as an intact sheet of cells) and endocervical epithelium (released as small clumps of cells) were placed in trypsin-EDTA for 20 min at 37°C with frequent agitation. The resulting cell suspensions
were centrifuged and resuspended at 2 × 105
ectocervical cells and 105 endocervical cells per ml in
keratinocyte-serum free medium (Gibco/Life Technology, Paisley, United
Kingdom). Cells were grown in 12-well plates at 37°C in a humidified
atmosphere containing 5% CO2 and refed every 2 days by
replacing half of the existing medium. Epithelial monolayers were
demonstrated to be viable and functional by growth characteristics,
structural and ultrastructural morphology (light and electron
microscopy), mitotic activity [incorporation of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
dye], and presence of cytokeratin markers (confirming cell origin)
[K13, stratified ectocervical cells; K18, columnar endocervical
cells] [data not shown]). The intestinal epithelial cell line I407
(American Type Culture Collection) was cultured in RPMI 10%.
Epithelial monolayers were exposed to cell-free virus (30 to 70 ng of
HIV p24 per ml, pretreated with DNase) or chronically infected cells
(pretreated with mitomycin C) for 2 or 24 h at 37°C in 5%
CO2. Epithelial monolayers were washed five times
immediately after exposure to cell-free HIV or chronically HIV-infected
cells and washed again 48 h later. Culture medium was collected
every 2 days for p24 ELISA. Eight days postinfection, monolayers were processed for PCR or cocultured with PM-1 T cells, seeded at a 1:1
ratio for 10 days for virus isolation. PM-1 T cells are susceptible to
both M- and T-tropic HIV, expressing both CXCR4 and CCR5 coreceptors.
Virus transmission across polarized epithelial sheets.
Ectocervical epithelial sheets (8 mm), isolated as described above,
were analyzed by light microscopy (×200) for any visible perforation
of the epithelial cell surface. Viability and functional analysis of
epithelial sheets was carried out as described above. In addition,
presence of functional intercellular junctions (which exclude inulin)
were demonstrated by the detection of inulin transfer following EGTA
treatment. Epithelial sheets were clamped in diffusion chambers
(12) consisting of two acrylic plates, each of which had a
central aperture (3.5-mm diameter) connected to vertical chambers
providing independent access to apical and basolateral surfaces. A
leakproof seal was obtained by the means of concentrally positioned
O-rings (6-mm diameter). Cell-free virus (30 to 70 ng of HIV p24 per
ml, equivalent to 105 TCID50) or chronically
infected cells in culture medium containing 0.5 mCi of
[14C] inulin were added to the apical chamber (1 ml),
while culture medium alone was added to the basolateral chamber, and
polarized tissue was incubated for 2 h at 37°C in 5%
CO2. Culture medium was subsequently withdrawn from apical
and basolateral chambers, and the epithelial tissue was removed. Medium
was tested for the presence of [14C]inulin, p24 antigen,
and infectious virus by coculture with PM-1 T cells. Epithelial layers
were washed, either processed for quantitative PCR or fixed in 3%
glutaraldehyde in PBS, and sent for processing for transmission
electron microscopy (TEM) (Department of Anatomy, St. George's
Hospital Medical School).
Measurement of tissue viability.
Potential toxicity of
virucidal agents was quantitated using the principle of MTT (Sigma) dye
reduction by viable explant tissue into a methanol soluble formazan
product. In brief, ectocervical explants (3-mm diameter) were incubated
in virucidal agent (0.01 to 100 µg/ml) overnight and subsequently
washed five times in PBS. Tissue was then either immediately tested for
viability (T1) or cultured on grids in EMEM for a further 5 days before
testing for viability (T6). To assess tissue viability, washed explants were incubated in medium containing MTT (250 µg/ml) for 3 h at 37°C. Tissue viability was determined by dividing the optical density
of the formazan product at 570 nm by the dry weight of the explant.
Toxicity was determined by comparison of viability between treated
explants and untreated control tissue. Virucidal agents were considered
to be nontoxic only at concentrations that demonstrated no reduction in
tissue viability at either T1 or T2. A minimum of three independent
experiments using tissue from separate donors were performed in
duplicate for each condition.
Immunohistochemistry.
Tissues were fixed overnight in
neutral buffered formalin, and 4-µm sections of paraffin-embedded
tissue were prepared. Endogenous peroxidase was inactivated in
deparaffinizsed sections with a 30-min treatment in methanol-0.3%
(vol/vol) H2O2. Antigens in paraffin sections
were unmasked with a 10-min treatment with pronase (Dako Ltd., High
Wycombe, United Kingdom). Slides were washed between incubations with
Tris-buffered saline. Slides were incubated with 20% (vol/vol) rabbit
serum in Tris-buffered saline for 30 min followed by overnight
incubation at 4°C with one of the following primary monoclonal
antibodies diluted in 20% (vol/vol) rabbit serum: anti-p24 (Kal-1),
CD2 (MT910), CD68 (PGM1), CD1a (NA1/34), CD45RO (OPD4), and mouse
immunoglobulin G1 (Dako) and major histocompatibility class II (WR18
[Serotec, Oxford, United Kingdom] and L243 [American Type Culture
Collection). Biotinylated rabbit anti-mouse immunoglobulin G antibody
(Dako) was applied to the sections, followed by avidin-biotin peroxidase complex (Dako) and diaminobenzidine (DAB) substrate (Sigma).
Sections were counterstained with Mayer's hematoxylin. For dual
immunohistochemistry with primary antibodies raised in the same
species, the above procedure was applied in two consecutive treatments.
Sections were not counterstained. The first monoclonal antibody was
detected with the peroxidase-DAB method. The procedure was then
repeated, starting at the pronase step, for the second monoclonal
antibody which was detected with avidin-biotin alkaline phosphatase
(Dako) and nitroblue tetrazolium salt and bromochloroindolylphosphate substrates (Sigma).
PCR for proviral DNA.
For PCR, DNA was extracted from cells
and tissues by an overnight digestion at 55°C and 5 min at 95°C
with 500 µg of proteinase K per ml, 0.1% (vol/vol) Nonidet P-40
(Sigma), and PCR buffer II (Perkin-Elmer, Warrington, United Kingdom).
Viral DNA was purified using QIAamp spin columns (Qiagen, Crawley,
United Kingdom). Qualitative PCR for HIV-1 DNA was carried out by
amplification of a 540-bp long terminal repeat LTR sequence
(5) which had a sensitivity of 10 copies per 105
cells. To control for sample quality and loading, duplicate PCRs were
carried out using primers for
-actin (forward primer, 5'-GAA GAT CAA
GAT CAT TGC TCC TCC-3'; reverse primer, 5'-CTG GTC TCA AGT CAG TGT ACA
GG-3') (GenBank accession no. M10277). Quantitative proviral PCR for
HIV-1 LTR DNA was carried out by real-time PCR on a ABI Prism 7700 sequence detection system as previously described (9). The
following reagents were used for this assay: LTR forward primer, 5'-CAC
ACA AGG CTA CTT CCC TGA-3' (59 to 79); LTR reverse primer, 5'-TCT CTG
GCT CAA CTG GTA CTA GCT T-3' (141 to 165); probe
5'-(6-carboxy-fluorescein [FAM])AGA ACT ACA CAC CAG GGC CAG GGA TCA
G(6-carboxy-tetramethyl-rhodamine [TAMRA])-3' (85 to 112) (based on
the reference sequence for HIV-1, isolate HXB2; GenBank accession no.
K03455);
-actin forward primer, 5'-TCA CCC ACA CTG TGC CCA TCT ACG
A-3' (486 to 510); reverse primer 5'-AGT CAG TCA GGT CCC GGC C-3' (567 to 585); probe 5'-(VIC proprietary dye [PE Applied Biosystems])ATG
CCC TCC CCC ATG CCA TCC TGC GT(Q) (TAMRA)-3' (GenBank accession no.
AB004047). Primers and FAM-labeled probe were obtained from MWG
Biotech, Ebersberg, United Kingdom, and VIC-labeled
-actin probe was
obtained from PE Applied Biosystems, Warrington, United Kingdom.
-actin was used as an internal control allowing normalization of HIV
copy number relative to the number of genome equivalents in the
specimen. The threshold sensitivity was 10 DNA copies per reaction.
 |
RESULTS |
HIV infection of genital mucosa is potentiated by immune
activation.
Susceptibility of female genital tract mucosa to HIV
infection was investigated in vitro using mucosal tissue explants,
obtained from seronegative premenopausal women undergoing hysterectomy as previously described (23). Ectocervical, endocervical,
and vaginal explants (3 mm3) were cultured under resting
(medium alone) or activating (in the presence of PHA and IL-2)
conditions. Explant tissue was exposed, in a nonpolarized manner, to
primary NSI and laboratory-adapted SI HIV-1 isolates with known
coreceptor restriction: BaL (NSI, CCR5/CCR3 restricted), IIIB, and RF
(SI, predominantly CXCR4 restricted). Ectocervical and
endocervical explant cultures were demonstrated to be susceptible to
infection with HIV-1BaL as indicated by increased accumulation of HIV p24 release independent of culture conditions (Fig.
1). In contrast, T-tropic strains of HIV
(IIIB and RF) induced significant levels of productive HIV infection
only in immune activated tissue. However, productive infection with
either IIIB or RF could still be rescued if tissue stimulation (with
PHA) was delayed by 8 days after exposure to HIV (Table
1). Persistence of HIV within explants
for 8 days prior to stimulation was dependent on HIV infection, as
these effects were inhibited in the presence of zidovudine. A similar
pattern of HIV replication was also observed in vaginal explants (data
not shown). To determine whether other primary isolates of HIV
replicated similarly to HIV-1BaL, ectocervical explants
were exposed to primary isolates SL-2 (NSI, predominantly CCR5
restricted), 2044 (SI, CXCR4 restricted), and 2076 (SI, dualtropic, able to use CCR5, CCR3, and CXCR4). Explants were inoculated with virus
within 4 h of obtaining tissue from surgery to minimize any
potential changes in coreceptor expression and cultured in the presence
or absence of activating conditions. Unlike HIV-1BaL (at an
equivalent dose [data not shown]), all three primary strains required
immune activation to induce significant levels of viral replication
(Fig. 2).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 1.
Kinetics of HIV replication in cervical
explant tissue. (A) Accumulation of HIV-1 DNA in ectocervical explants
was determined 7 days after infection with HIV-1BaL,
HIV-1IIIB, or HIV-1RF as assayed for LTR DNA by
quantitative real-time PCR as described in Materials and Methods.
Explants either were prestimulated with PHA 2 days prior to HIV
infection and subsequently cultured with IL-2 (filled bars) or were
cultured in medium alone before and after infection (open bars). Data
represents the mean and standard error of three independent experiments
using paired explants from separate donors. p24 antigen release from
ectocervical (B) and endocervical (C) explants was measured by
ELISA. Explants were cultured either alone (open symbols, solid lines)
or prestimulated with PHA (5 µg/ml) 2 days prior to viral exposure
and restimulated 8 days post exposure. Stimulated explants were
cultured in the presence of IL-2 (10 U/ml) (closed symbols, broken
lines). Explants were exposed to HIV-1BaL
(105 TCID50) without ( ) or with ( ) (PHA,
HIV-1IIIB (106 TCID50) without
( ) or with ( ) PHA, or HIV-1RF
(106TCID50) without ( ) or with ( ) PHA.
Data represent the mean from a minimum of three independent experiments
using paired explants from separate donors. (t test;
*, P = <0.05; **, P = <0.01).
|
|

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 2.
Replication of primary HIV isolates in cervical explant
tissue. Ectocervical explants were exposed to HIV-1 isolates SL-2
(M-tropic, NSI, CCR5 restricted), 2044 (T-tropic, SI, CXCR4
restricted), or 2076 (dualtropic, SI, able to use CCR5, CCR3, and
CXCR4) by immersion in cell-free virus (103
TCID50) for 2 h at 37°C. Subsequently explant
tissue was washed in PBS, and tissue was directly transferred to
96-well plates, where they were cultured in medium alone (RPMI 10%)
(open bars) or stimulated by culture in the presence of PHA (5 µg/ml)
for 2 days and subsequently refed with medium containing IL-2 (filled
bars). Data are shown as p24 antigen release (mean ± standard error) 14 days postinfection and represent the mean from a
minimum of three independent experiments using paired explants from
separate donors.
|
|
Primary target cells of HIV infection within genital mucosa.
Mucosal explants were processed for immunohistochemistry 7 days after
in vitro exposure to HIV isolates to determine the primary target cells
of HIV infection within genital mucosa. In a previous study, we have
described the normal cellular distribution of immune cells in
such cultures (23). Such studies demonstrated that CD1a
Langerhans cells are exclusively found in cervical eithelium, CD3
cells are predominantly detected in the mucosa, closely associated with
the epithelium, and CD14/68-positive macrophages are restricted to
subepithelial mucosa. Analysis of tissue infected with M-tropic HIV-1BaL, in the absence or presence of stimulation,
demonstrated numerous cells, within cervical subepithelial mucosa,
positive for HIV p24 expression (Fig.
3A). The majority
(>90%) of these cells were dual positive for p24 expression and the
macrophage marker CD68 (Fig. 3C). Few p24 cells were positive for CD3
expression, and there was no difference in their frequency between
activated or resting explants. Some p24-positive cells were detected in immune activated cervical tissue exposed to T-tropic HIV isolates (IIIB
and RF); however, their frequency was far lower than that seen with
M-tropic strain of BaL, and it was not possible to determine their
phenotype (Fig. 3B). HIV-infected epithelial cells or CD1a-positive Langerhans cells were not detected by immunohistochemistry in any
HIV-exposed explants; furthermore, in all experiments no p24-positive cells were ever detected in the epithelium regardless of their phenotype.

View larger version (71K):
[in this window]
[in a new window]
|
FIG. 3.
(A and B) Immunohistochemical staining of p24 expression
(blue/purple) in an ectocervical explant 7 days after infection with
HIV-1BaL (A) and HIV-1RF (B). (C) Dual staining
for p24 expression (blue/purple) and macrophage marker CD68 (brown) in
an ectocervical explant 7 days after infection with
HIV-1BaL. Original magnification for all panels, ×400.
|
|
Lack of evidence for epithelial infection or transcytosis of
HIV.
Further investigations were carried out to exclude a low
level of HIV infection of genital epithelial cells. In vitro
cultures of primary ectocervical and endocervical monolayers were
established based on previously described methods (37).
Epithelial monolayers were exposed to either cell-free M-tropic
HIV-1BaL or T-tropic HIV-1RF, or to
cell-associated HIV in the form of PM-1 cells (a T-cell line expressing
both CCR5 and CXCR4 coreceptors) or human PBMC, chronically infected
with either BaL or RF. The human intestinal epithelial cell line I407,
previously demonstrated to be susceptible to HIV infection and to
transcytose HIV (1, 25) was used as a positive control.
Primary cultures of ectocervical and endocervical epithelial
monolayers, unlike I407 cells, were resistant to HIV infection with
either cell-free or cell-associated M- or T-tropic virus (Table
2). Furthermore, no evidence of
endocytosis was detected by TEM of primary ectocervical, endocervical,
or vaginal epithelium following 6 and 24 h of exposure to either
cell-associated or cell-free HIV (data not shown). In contrast, I407
cells were susceptible to infection with cell-free or cell-associated
HIV-1RF but resistant to HIV infection with either
cell-free or cell-associated HIV-1BaL. Furthermore, while
transient adherence of lymphocytes to I407 cells was detectable (Fig.
4A), adherence of such
cells to primary genital epithelium was either very infrequent or not detectable by either light or electron microscopic analysis of primary
epithelial cultures (Fig. 4B and C).

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 4.
(A) TEM showing lymphocyte adherence to I407 epithelial
monolayer (original magnification, ×7,800). Experiments representative
of a minimum of five explants for each condition. (B) TEM showing
ultrastructure of stratified cervical ectocervical epithelium following exposure to PM-1
T cells infected with HIV-1BaL (original magnification,
×260). The epithelial sheet has been removed from underlying stroma
following overnight treatment with dispase. Epithelial tissue was
exposed to cell-associated virus for 2 h in the described
diffusion chamber and gently washed before processing for TEM. There is
no evidence of adherence or penetration of PM-1 T cells into the
epithelium (experiment representative of three). (C) TEM showing single
endocervical epithelial monolayer following exposure to PBMC infected
with HIV-1BaL (original magnification, ×1,200). Epithelial
cells contain multiple mucus-containing vesicles and express multiple
microvilli on their apical surface. Endogenous mononuclear cells can be
seen in the underlying stromal tissue. The epithelial tissue was
exposed to PBMC infected with HIV-1BaL for 2 h and
processed as described above. There is no evidence of adherence of
paracellular migration of donor PBMC (experiment representative of
five).
|
|
Polarized genital epithelium is impervious to cell-free or
cell-associated HIV.
To determine whether HIV can cross intact
genital epithelium, epithelial sheets were polarized using a diffusion
chamber allowing independent bathing of apical and basolateral
epithelial surfaces as previously described (12). Such a
system facilitated apical exposure of epithelial surfaces to HIV, as
presented in vivo. Ectocervical stratified epithelial sheets were
isolated following overnight digestion with dispase as previously
described. Integrity of epithelial surfaces was assessed prior to
experiments by direct light microscopic examination of the mucosal
surface and permeability assessed during experiments by
[14C]inulin diffusion. Polarized cultures of ectocervical
epithelial sheets were exposed to cell-free or cell-associated HIV as
described above. Measurement of basolateral p24 release and infectious
coculture assays demonstrated that stratified epithelium, which
excluded [14C]inulin, was impervious to cell-free or
cell-associated HIV (Table 3).
Furthermore, TEM analysis of polarized ectocervical and endocervical tissue exposed to either cell-free or cell-associated HIV demonstrated no evidence of HIV transcytosis or paracellular penetration of either
cell-free HIV or HIV-infected cells. In addition, no interaction between exogenous HIV-infected mononuclear cells and epithelium was
observed. Lack of paracellular penetration of cervical epithelial sheets by HIV-infected mononuclear cells was confirmed by demonstration that epithelial sheets were negative, by PCR, for proviral DNA following exposure to such infected cells (data not shown).
Vaginal virucides block HIV infection of genital mucosa.
Further investigations were carried out to determine the efficacy of
potential virucides to block HIV infection of cervical explants.
Compounds included nonoxynol-9 (N-9; a nonionic surfactant known to be
active against HIV and other sexually transmitted agents
[36]), gramicidin (GD; a peptide antibiotic with
virucidal activity [2]), and PRO 2000 (a naphthalene
sulfonate polymer that appears to disrupt the initial binding
and fusion events of HIV infection [32]). Agents
were tested (range, 100 to 0.01 µg/ml) for potential tissue toxicity
following overnight culture with ectocervical explants. Viability of
cervical explants, assessed by MTT assay, was reduced following
exposure to N-9 or GD at concentrations of >1 µg/ml, while PRO 2000 demonstrated no toxicity at 100 µg/ml (data not shown). As potential
virucidal agents should demonstrate no tissue toxicity, which
could reduce barrier effects of genital epithelium, for all subsequent
investigations we used N-9 and GD at 1 µg/ml and PRO 2000 at 100 µg/ml. To determine the efficacy of these agents to block HIV
infection of cervical tissue, explants were preincubated with virucides
for 1 h prior to overnight exposure to virus in the continued
presence of virucidal agent. Explants were exposed to virus in a
nonpolarized manner, allowing direct access to both subepithelial and
epithelial cells, analogous to conditions of compromised genital
epithelium in vivo. Following overnight exposure to virus,
explants were washed to remove any exogenous virus and virucidal agent
and subsequently cultured for 10 days in the presence or absence of
activating conditions prior to measurement of p24 production and
proviral accumulation. Presence of N9, GD, and PRO 2000 during exposure
of ectocervical explants to HIV-1BaL (105
TCID50/ml) resulted in a 30%, 71%, and 97% inhibition of
p24 production, respectively. PRO 2000 was the only agent to completely block proviral formation, as determined by PCR, and this agent was also
able to efficiently block HIV infection with three other primary HIV
strains, SL-2, 2044, and 2076, under activating conditions (PHA and
IL-2) (Fig. 5).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of vaginal virucides on HIV-infected genital
mucosa. Cervical explants were preincubated with the virucidal agent
N-9 (1 µg/ml), GD (1 µg/ml), or PRO 2000 (100 µg/ml) for 1 h
prior to overnight exposure to HIV-1 strain BaL ( ; 105
TCID50/ml), SL2 ( ), 2044 ( ), or 2076 ( ) (all
103 TCID50/ml) in the continued presence of the
virucidal agent. Explants were exposed to virus in a nonpolarized
manner, allowing direct access to both subepithelial and epithelial
cells. Following overnight exposure to viral inoculum, explants were
washed extensively in PBS, stimulated by culture in the presence of PHA
(5 µg/ml) for 2 days, subsequently refed with medium containing IL-2,
and cultured for 14 days. Data represent percent inhibition of p24
production at day 14 of culture, compared to control cultures exposed
to virus in the absence of virucidal agent, and are presented as the
mean of five independent experiments using explants from separate
donors. Detection of proviral DNA by PCR at the right is shown as
number of experiments with detectable proviral DNA out of the total
tested (limit of detection, 10 copies/explant).
|
|
 |
DISCUSSION |
HIV infection of genital mucosa is enhanced by immune
activation.
The observation that immune activation (PHA and IL-2)
enhanced HIV infection, using a range of viral isolates (RF, IIIB,
2044, 2076, and SL-2), suggests that transmission and productive
infection of genital mucosa are likely to be enhanced by concomitant
immune activation in vivo. Thus, infection with STDs resulting in local inflammation, and activation of local inflammatory cells potentially renders an individual more susceptible to HIV infection. Such observations fit with reported epidemiological evidence of a
correlation between STDs and HIV infection (10, 19),
although this was not observed by others (41). Furthermore,
our in vitro studies are supported by recent studies demonstrating an
association between STDs and increased CD4 levels and coreceptor
expression in genital mucosa (16, 24, 30). Demonstration
that these isolates can establish productive HIV infection of cervical
explants even if immune activation is delayed up to 8 days after in
vitro exposure suggests that immune stimulation caused by venereal
infection in vivo potentially facilitates and amplifies localized HIV
infection subsequent to the transmission event. It is beyond the scope
of this experimental model to determine how long such a reservoir of
localized HIV infection may persist; however, the potential ability of
venereal infection to activate localized HIV infection in this manner
has serious implications for transmission of HIV.
In contrast to the isolates mentioned above, HIV-1BaL (able
to use both CCR5 and CCR3 coreceptors) infected and replicated in both
immunologically silent and activated cervical tissue with equal
efficiency. The ability of HIV-1BaL to replicate
efficiently in cervical tissue, without immune activation, is unlikely
to be coreceptor dependent, determined by V3 hypervariable regions of
the viral envelope, since both SL-2 and 2076 can efficiently utilize
CCR5, and 2076 can utilize CCR3 (34). Furthermore, such preferential replication is unlikely to be dependent on macrophage tropism, as SL-2, 2044, and 2075 can all infect macrophages in vitro
(34). It is possible that the observed preferential
replication of HIV-1BaL may reflect expression of sequences
within V1 and V2 hypervariable regions that appear to modulate
efficiency of viral spread in macrophages (39). Indeed,
recent observations that a concentration-dependent direct or indirect
interaction between CCR5 and CD4 governs HIV infection of macrophages
(26) suggests that in the absence of increased CD4 and CCR5
levels stimulated by concomitant immune activation (16, 24,
30), such regions outside V3 may provide a selective advantage
for infection of genital tissue. The contribution of such regions to
HIV infection of cervical tissue is the subject of ongoing investigations. However, primary isolates of HIV demonstrating a
similar replicative fitness for infection of genital tissue macrophages
in vivo would have a selective advantage for both infection and
amplification within genital mucosa and would be likely to predominate
in peripheral blood during acute infection. This would be in keeping
with a selective amplification model of HIV transmission
(33).
In contrast, isolates lacking such a potential selective advantage for
replication in mucosal tissue might remain localized in genital mucosa
at undetectable levels until amplified by immune activation following
coincidental or subsequent infection with other STDs. Such findings
correlate with the observation that recently infected women display a
genotypic diversity in HIV populations isolated from genital secretions
not reflected in peripheral blood (28).
Prime target cells for HIV infection of the female genital
tract.
The described study has confirmed that subepithelial cells
are the prime target cells for HIV infection in female genital tract
mucosal tissue in organ culture. Furthermore dual immunohistochemistry identified the majority of HIV-infected cells as subepithelial macrophages. Thus, these cells may represent the main target cells for
HIV infection in the female genital tract. There was no evidence of HIV
infection of cells within the cervical epithelium. This is in keeping
with numerous previous studies demonstrating that following vaginal
transmission of either HIV or SIV, infection is exclusively restricted
to the subepithelial cells (20, 21, 23, 27, 35). The lack of
HIV infection within the epithelium is highly likely to reflect recent
observations that expression of CCR5, CCR3, and CXCR4 in cervical
tissue is predominantly restricted to subepithelial cells (24,
44). However, it cannot be excluded that cell populations within
the epithelium can harbor viral infection below limits of detection by immunohistochemistry.
Resistance of human endocervical, ectocervical, and vaginal epithelial
cells to HIV infection, on exposure to cell-free or cell-associated
HIV, was confirmed by PCR (able to detect 10 copies per 105
cells), infectious coculture, and p24 release using primary epithelial cell lines. While an extremely low level of infection cannot be completely excluded, such observations contrast to previous reports of
productive infection utilizing transformed epithelial cell lines
(38). Chenine et al. recently reported that intestinal epithelial cells could be productively infected with laboratory (HIV-1NDK) but not primary HIV isolates (4).
Such data suggest that strain differences may determine differing
tropism for epithelial cells. However, our observation that
HIV-1RF and HIV-1NDK (data not shown), able to
infect intestinal cells, did not infect cervical epithelial cells
suggests that the adaptation required for infection of intestinal cells
is not transferable to those of the cervix. Such differences are more
likely to reflect the lack of CXCR4 expression within the cervical
epithelium (24, 44), previously demonstrated to be required
for infection of intestinal epithelial (6). These results
are in agreement with the consistent inability to detect HIV infection
of genital epithelial cells in vivo (20, 21, 23, 27, 35) but
contrast to reported detection of infected intestinal cells in vivo
(17). One study has previously suggested that genital
epithelial cells may be susceptible to HIV infection ex vivo
(13), as demonstrated by immunohistochemical localization.
Differences between this previous report and ours demonstrating a lack
of infection by immunohistochemistry, proviral PCR, p24 production, and
infectious coculture assay may reflect differences in the purity of
epithelial cultures and/or effectiveness in the elimination of
nonspecific sticking of virus to the membrane of epithelial cells in
the absence of productive infection. While transcytosis of HIV has been
demonstrated in intestinal epithelial cell lines (1),
extrapolation of these mechanisms to heterosexual transmission via
intact genital mucosa would be premature. Indeed, data presented in
this study demonstrate no evidence for transcytosis of HIV across
primary human endocervical, ectocervical, and vaginal epithelial cell
layers, strongly suggesting that transcytosis is not a major mechanism
of transepithelial penetration across the female genital mucosa. Such
findings are perhaps unsurprising since a principal strategic function
of genital epithelium is protection from infection. Indeed, intestinal
epithelial cells bear little resemblance to genital epithelial cells,
being derived from endoderm, expressing no keratin markers, lacking
stratification, and unlike genital epithelium, having a highly active
endocytic phenotype. Thus, it is unlikely that genital epithelium would take on the transport function of specialized intestinal cells such as
enterochromaffin cells reported to be infected in the rectal mucosa of
HIV-positive subjects (17).
Other studies, using epithelial cell lines or animal models, have
suggested that donor HIV-infected cells may themselves invade genital
mucosa (14, 43). In this study, we observed that while PBMC
transiently adhered to the I407 intestinal epithelial cell line,
adherence to primary endocervical or ectocervical epithelial cultures
was not detected. Furthermore, there was no evidence of HIV-infected
donor cell migration into either ectocervical, endocervical, or vaginal
tissue, as assessed by light and electron microscopy and by PCR for
proviral DNA. Thus, an active role for either epithelia or migration of
donor cells in transmucosal penetration of HIV appears unlikely in
our in vitro model. In contrast, the weight of evidence presented in
this study suggests that intact normal cervical and vaginal epithelial
cells, in the absence of inflammatory stimuli, provide a barrier to
both cell-free and cell-associated HIV. Thus, transmission of HIV
infection at such tissue sites is likely enhanced by any physical
breach in epithelial integrity, such as might be caused by physical
abrasion, ulceration, or inflammation. This conclusion is supported by
observations that factors which have the potential to decrease
epithelial integrity, in particular, (i) epithelial ulceration
following venereal infection and (ii) cervical ectopy which may leave
tissue more friable, are associated with increased rates of HIV
transmission (31, 33). Furthermore, while this study
provides no evidence of HIV infection of epithelial Langerhans cells,
their potential role in passive transfer of HIV across genital
epithelium cannot be excluded (29).
The demonstration in this study that the target cells for HIV infection
in genital mucosal tissue are exclusively found directly below genital
epithelium, and that genital epithelial cells are resistant to HIV
infection, strongly suggest that intact genital epithelium provides a
barrier to HIV transmission. Strategies designed to protect genital
epithelium are highly likely to have a major impact on heterosexual
transmission rates. In this respect, aggressive syndromic management of
STDs has been demonstrated in a Tanzanian trial to reduce HIV
transmission rates by 42% (10). Entry of HIV through
epithelial breaches would be unlikely to provide selective genotypic or
phenotypic pressure on the heterogeneity of transmitted virus. Indeed,
data reported here suggest that such pressure is likely to come from
localized levels of immune activation, influencing coreceptor
expression, and/or selective amplification of strains able to
efficiently replicate in genital tissue in the absence of immune
stimulation. Thus, potential virucides designed to block HIV infection
should demonstrate no tissue toxicity, which could reduce barrier
effects of genital epithelium, should not induce inflammation, and
should be active even when epithelial integrity is compromised and/or
under inflammatory conditions. Recent studies to evaluate safety
and tolerability of intravaginal N-9 have suggested that its use may
cause adverse effects including inflammation and reduction in numbers
of lactobacilli (36). Thus, in this study, all virucidal
agents were used at concentrations demonstrated not to be toxic to
cervical tissue. N-9 and GD, when used at nontoxic concentrations, did
not provide complete protection from HIV infection in vitro. In
contrast, the virucidal agent PRO 2000 at a concentration of 100 µg/ml efficiently blocked HIV infection of cervical tissue under
conditions which mimic both compromised epithelial integrity and
inflammatory conditions. Previous studies have detected up to
107 HIV-1 RNA copies/ml of semen (11); however,
this is unlikely to reflect the level of infectious virions. Indeed,
quantitative microculture methods have demonstrated levels of only up
to 104 infectious units per ejaculate (7). Thus,
the demonstration that PRO 2000, at a concentration of 100 µg/ml,
provided complete protection against a viral inoculum with a
TCID50 of 105/ml suggests that this agent is
highly likely to provide protection against any natural inoculum.
Furthermore, such studies were carried out using a concentration of PRO
2000 that is 400 times less than that currently proposed for
intravaginal use.
These studies demonstrate that the described cervical explant model of
HIV infection represents a suitable model for evaluation of potential
virucidal agents. Furthermore, this is the first demonstration that
virucidal agents can effectively block HIV infection of genital tissue.
In the absence of the imminent approval of an effective mucosal
vaccine, use of such virucidal agents, designed to provide women with
unobtrusive protection, is likely to have a major impact on global
heterosexual transmission rates and may also prove useful in prevention
of vertical transmission.
We are grateful to A. Wilson and R. Moss for electron microscopy, to
Isaac Manyonda and Deborah Moncrieff and the Obstetrics and Gynaecology
Departments of St. George's and St. Helier's Hospitals for assistance
in obtaining cervical tissue, and to C. Corbishley and staff of the
Histopathology Department at St. George's Medical School. We thank
Paul Clapham (Institute for Cancer Research, London) for viral isolates
SL2, 2044, and 2076, Procept for donation of PRO 2000, and London
International Group for N9. We also thank the Medical Research Council
(MRC) AIDS Reagent Project for supply of many reagents used in this study.
This work was supported by MRC grants G9428495 and G9828308 and is part
of the MRC cooperative grant on intracellular pathogens (COGG-G9814061).
| 1.
|
Bomsel, M.
1997.
Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier.
Nat. Med.
3:42-47[CrossRef][Medline].
|
| 2.
|
Bourinbaiar, A., and S. Lee-Huang.
1994.
Comparative in vitro study of contraceptive agents with anti-HIV activity: gramicidin, nonoxynol-9, and gossypol.
Contraception
49:131-137[CrossRef][Medline].
|
| 3.
|
Burkhard, M.,
L. Obert,
L. O'Neil,
L. Diehl, and E. Hoover.
1997.
Mucosal transmission of cell-associated and cell-free feline immunodeficiency virus.
AIDS Res. Hum. Retroviruses
13:347-355[Medline].
|
| 4.
|
Chenine, A.,
E. Matouskova,
G. Sanchez,
J. Reischig,
L. Pavlikova,
C. LeContel,
J. Chermann, and I. Hirsch.
1998.
Primary intestinal epithelial cells can be infected with laboratory-adapted strain HIV type 1 NDK but not with clinical primary isolates.
AIDS Res. Hum. Retroviruses
14:1235-1238[Medline].
|
| 5.
|
Collin, M.,
W. James, and S. Gordon.
1991.
Development of techniques to analyse the formation of HIV provirus in primary human macrophages.
Res. Virol.
142:105-112[CrossRef][Medline].
|
| 6.
|
Delezay, O.,
N. Koch,
N. Yahi,
D. Hammache,
C. Tourres,
C. Tamalet, and J. Fantini.
1997.
Co-expression of CXCR4/fusin and galactosylceramide in the human intestinal epithelial cell line HT-29.
AIDS
11:1311-1318[CrossRef][Medline].
|
| 7.
|
Dyer, J.,
B. Gilliam,
J. Eron,
L. Grossi,
M. Cohen, and S. Fiscus.
1996.
Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with qantitative culture.
J. Virol. Methods
60:161-170[CrossRef][Medline].
|
| 8.
|
Elias, C., and C. Coggins.
1996.
Female-controlled methods to prevent sexual transmission of HIV.
AIDS
10:S43-S51.
|
| 9.
|
Esser, M.,
M. Toshiyuki,
I. Mondor,
Q. Sttentau,
B. Dey,
E. Berger,
M. Boyd, and J. Lifson.
1999.
Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type-1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
J. Virol.
73:4360-4371[Abstract/Free Full Text].
|
| 10.
|
Grosskurth, H.,
F. Mosha,
J. Todd,
E. Mwijarubi,
A. Klokke,
K. Senkoro,
P. Mayaud,
J. Changalucha,
A. Nicoll,
G. ka-Gina, et al.
1995.
Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial.
Lancet.
346:530-536[CrossRef][Medline].
|
| 11.
|
Gupta, P.,
J. Mellors,
L. Kingsley,
S. Riddler,
M. Singh,
S. Schreiber,
M. Cronin, and C. Rinaldo.
1998.
Hifh viral load in semen of human immunodeficiency virus type-1 infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors.
J. Infect. Dis.
71:6271-6275.
|
| 12.
|
Herbert, C.,
D. Edwards,
J. Boot, and C. Robinson.
1991.
In vitro modulation of the eosinophil-dependent enhancement of the permeability of the bronchial mucosa.
Br. J. Pharmacol.
104:391-398[Medline].
|
| 13.
|
Howell, A.,
R. Edkins,
S. Rier,
G. Yeaman,
J. Stern,
M. Fanger, and C. Wira.
1997.
Human immunodeficiency virus type 1 infection of cells and tissues from the upper and lower human female reproductive tract.
J. Virol.
71:3498-3506[Abstract].
|
| 14.
|
Ibata, B.,
E. Parr,
N. King, and M. Parr.
1997.
Migration of foreign lymphocytes from the mouse vagina into the cervicovaginal mucosa and to the iliac lymph nodes.
Biol. Reprod.
56:537-543[Abstract].
|
| 15.
|
Kitano, Y., and N. Okada.
1983.
Separation of the epidermal sheet by dispase.
Br. J. Dermatol.
108:555-560[CrossRef][Medline].
|
| 16.
|
Levine, W.,
V. Pope,
A. Bhoomkar,
P. Tambe,
J. Lewis,
A. Zaidi,
C. Farshy,
S. Mitchell, and D. Talkington.
1998.
Increase in endocervical CD4 lymphocytes amoung women with nonulcerative sexually transmitted diseases.
J. Infect. Dis.
177:167-174[Medline].
|
| 17.
|
Levy, J.,
W. Margaretten, and J. Nelson.
1989.
Detection of HIV in enterochromaffin cells in the rectal mucosa of an AIDS patient.
Am. J. Gastroenterol.
84:787-789[Medline].
|
| 18.
|
Marx, P.,
A. Spira,
A. Gettie,
P. Dailey,
R. Veazey,
A. Lackner,
C. Mahoney,
C. Miller,
L. Claypool,
D. Ho, and N. Alexander.
1996.
Progesterone implants enhance SIV vaginal transmission and early virus load.
Nat. Med.
2:1084-1089[CrossRef][Medline].
|
| 19.
|
Miller, C.
1998.
Host and viral factors influencing heterosexual HIV transmission.
Rev. Reprod.
3:42-51[Abstract].
|
| 20.
|
Miller, C.,
P. Vogel,
N. Alexander,
S. Sutjipto,
A. Hendickx, and P. Marx.
1992.
Localization of SIV in the genital tract of chronically infected female rhesus macaques.
Am. J. Pathol.
141:655-660[Abstract].
|
| 21.
|
Nuovo, G.,
A. Forde,
P. MacConnell, and R. Fahrenwald.
1993.
In situ detection pf PCR-amplified HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical tissues.
Am. J. Pathol.
143:40-48[Abstract].
|
| 22.
|
Padian, N.,
S. Shiboski,
S. Glass, and E. Vittinghoff.
1997.
Heterosexual transmission of human immunodeficiency viruss (HIV) in northern California: results of a ten-year study.
Am. J. Epidemiol.
146:350-357[Abstract/Free Full Text].
|
| 23.
|
Palacio, J.,
B. Souberbielle,
R. Shattock,
G. Robinson,
I. Manyonda, and G. Griffin.
1994.
In vitro HIV-1 infection of human cervical tissue.
Res. Virol.
145:155-161[Medline].
|
| 24.
|
Patterson, B.,
A. Landay,
J. Andersson,
C. Brown,
H. Behbahani,
D. Jiyamapa,
Z. Burki,
D. Stanislawski,
M. Czerniewski, and P. Garcia.
1998.
Repertoire of chemokine receptor expression in the female genital tract.
Am. J. Pathol.
153:481-490[Abstract/Free Full Text].
|
| 25.
|
Phillips, D., and A. Bourinbaiar.
1992.
Mechanism of HIV spread from lymphocytes to epithelia.
Virology
186:261-273[CrossRef][Medline].
|
| 26.
|
Platt, E.,
K. Wehrly,
S. Kuhmann,
B. Chesebro, and D. Kabat.
1998.
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immundeficiency virus type 1.
J. Virol.
72:2855-2864[Abstract/Free Full Text].
|
| 27.
|
Pomerantz, R.,
S. de la Monte,
S. Donegan,
T. Rota,
M. Vogt,
D. Craven, and M. Hirch.
1988.
Human immunodeficiency virus (HIV) infection of the uterine cervix.
Ann. Intern. Med.
108:321-327.
|
| 28.
|
Poss, M.,
H. Martin,
J. Kreiss,
L. Granville,
B. Chohan,
P. Nyange,
K. Mandaliya, and J. Overbaugh.
1995.
Diversity of populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1.
J. Virol.
69:8118-8122[Abstract].
|
| 29.
|
Reece, J.,
A. Handley,
E. Anstee,
W. Morrison,
S. Crowe, and P. Cameron.
1998.
HIV-1 selection by epidermal dendritic cells during transmission across human skin.
J. Exp. Med.
187:1623-1631[Abstract/Free Full Text].
|
| 30.
|
Rottman, J.,
K. Ganley,
K. Williams,
L. Wu,
C. Mackay, and D. Ringler.
1997.
Cellular localization of the chemokine receptor CCR5.
Am. J. Pathol.
151:1341-1351[Abstract].
|
| 31.
|
Royce, R.,
M. Sena,
W. Cates, and M. Cohen.
1997.
Sexual transmission of HIV.
N. Engl. J. Med.
336:1072-1078[Free Full Text].
|
| 32.
|
Rusconi, S.,
M. Moonis,
D. Merrill,
P. Pallai,
E. Neidhardt,
S. Singh,
K. Willis,
M. Osburne,
A. Profy,
J. Jenson, and M. Hirsch.
1996.
Naphthalene sulphonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities.
Antimicrob. Agents Chemother.
40:234-236[Abstract].
|
| 33.
|
Shattock, R., and G. Griffin.
1996.
Mucosal transmission of human immunodeficiency virus, p. 25-38.
In
A. Lever (ed.), The molecular biology of HIV/AIDS. John Wiley & Sons, Ltd., Chichester, England.
|
| 34.
|
Simmons, G.,
J. Reeves,
A. McKnight,
N. Dejucq,
S. Hibbitts,
C. Power,
E. Aarons,
D. Schols,
E. Clercq,
A. Proudfoot, and P. Clapham.
1998.
CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages.
J. Virol.
72:8453-84577[Abstract/Free Full Text].
|
| 35.
|
Spira, A. I.,
P. A. Marx,
B. K. Patterson,
J. Mahoney,
R. A. Koup,
S. M. Wolinsky, and D. D. Ho.
1996.
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques.
J. Exp. Med.
183:215-25[Abstract/Free Full Text].
|
| 36.
|
Stafford, M.,
H. Ward,
A. Flanagan,
I. Rosenstein,
D. Taylor-Robinson,
J. Smith,
J. Weber, and V. Kitchen.
1998.
Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
17:327-331[Medline].
|
| 37.
|
Stanley, M., and I. Greenfield.
1992.
Culture of human cervical epithelial cells, p. 135-158.
In
R. Freshney (ed.), Culture of epithelial cells. Wiley-Liss, Inc., New York, N.Y.
|
| 38.
|
Tan, X., and D. Philips.
1996.
Cell-mediated infection of cervix derived epithelial cells with primary isolates of human immunodeficiency virus.
Arch. Virol.
141:1177-1189[CrossRef][Medline].
|
| 39.
|
Toohey, K.,
K. Wehrly,
J. Nishio,
S. Perryman, and B. Chesebro.
1995.
Human immunodeficiency envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread.
Virology
213:70-79[CrossRef][Medline].
|
| 40.
|
Van't Wout, A.,
N. Kootstra,
G. Mulder-Kampinga,
N. Lent,
H. Scherpbier,
J. Veenstra,
K. Boer,
R. Coutinho,
F. Miedema, and H. Schuitemaker.
1994.
Macrophage-tropic varients initiate human immunodeficiency virus type-1 infection after sexual, parenteral and vertical transmission.
J. Clin. Investig.
94:2060-2067.
|
| 41.
|
Wawer, M.,
N. Sewankambo,
D. Serwadda,
T. Quinn,
L. Paxton,
N. Kiwanuka,
F. Wabwire-Mangen,
C. Li,
T. Lutalo,
F. Nalugoda,
C. Gaydos,
L. Moulton,
M. Meehan,
S. Ahmed, and R. Gray.
1999.
Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomized community trial.
Lancet
353:525-535[CrossRef][Medline].
|
| 42.
|
Wortley, P., and P. Flemming.
1997.
AIDS in women in the United States.
JAMA
278:911-916[Abstract].
|
| 43.
|
Zacharopoulis, V.,
M.-E. Perotti, and D. Phillips.
1997.
A role for cell migration in the sexual transmission of HIV-1.
Curr. Biol.
7:534-537[CrossRef][Medline].
|
| 44.
|
Zhang, L.,
T. He,
A. Talal,
G. Wang,
S. Frankel, and D. Ho.
1998.
In vivo distribution of human immunodeficiency virus/simian immunodeficiency virus coreceptors:CXCR4, CCR3, and CCR5.
J. Virol.
72:5035-5045[Abstract/Free Full Text].
|